A clinical research of Apatinib unite chemotherapy in second-line treatment of advanced lung cancer, gastric cancer and colorectal cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-16009458

Enrollment

Unknown

Registered

2016-10-17

Start date

2016-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Case series:combination of apatinib based on the second-line chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years old; 2. Pathologically diagnosed with advanced cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring >=10mm on spiral CT scan, tisfying the criteria in RECIST 1.1); 3. Failure of prior therapy (during or after treatment) in patients who have received at least two prior chemotherapy regimens; 4. A line of standard chemotherapy failure patients; 5. Patient has to voluntarily join the study sign the Informed Consent Form for the study.

Exclusion criteria

Exclusion criteria: 1. patients who are allergic to lapatinib or any of the ingredients in lapatinib tablets; 2. Pregnant or lactating women; 3. patients with contraindication; 4. patients who physicians suggest not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
Progression-Free-Survival;disease control rates;objective response rate;	—

Countries

China

Contacts

Public ContactQian Jun

Suzhou City Hospital

byqj@medmail.com.cn+86 13951702380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026